Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Researchers Explore Potential Strategy for Overcoming Resistance to RAS Inhibitors

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ascopost.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

Researchers at Roswell Park Comprehensive Cancer Center identified that resistance to KRAS-targeted cancer therapies can be overcome by co-targeting cell-cycle regulators CDK4/6 or CDK2, restoring sensitivity and improving treatment durability in preclinical models.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 2 Nov 2026 and 4 Nov 2026.

◆ ◆ The Wire takeaway

You must rethink KRAS inhibitor strategies to include cell-cycle blockers like CDK4/6 inhibitors to outsmart tumour resistance. This combo approach opens a fresh path for durable treatment success in tough cancers.

◆ Coverage

2 sources · first reported 2 Nov 2026 · latest 4 Nov 2026

◆ Related on Wire

◆ Topics

Biotechkrascancer-therapydrug-resistancecell-cyclecdk4-6